Grandfield & Dodd LLC purchased a new stake in shares of West Pharmaceutical Services, Inc. (NYSE:WST) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 2,088 shares of the medical instruments supplier’s stock, valued at approximately $201,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Vanguard Group Inc. lifted its holdings in West Pharmaceutical Services by 1.8% during the 2nd quarter. Vanguard Group Inc. now owns 6,555,351 shares of the medical instruments supplier’s stock worth $619,612,000 after purchasing an additional 114,507 shares in the last quarter. BlackRock Inc. lifted its holdings in West Pharmaceutical Services by 7.1% during the 2nd quarter. BlackRock Inc. now owns 6,217,894 shares of the medical instruments supplier’s stock worth $587,715,000 after purchasing an additional 412,858 shares in the last quarter. State Street Corp lifted its holdings in West Pharmaceutical Services by 2.8% during the 2nd quarter. State Street Corp now owns 2,511,108 shares of the medical instruments supplier’s stock worth $237,351,000 after purchasing an additional 67,937 shares in the last quarter. Goldman Sachs Group Inc. lifted its holdings in West Pharmaceutical Services by 10.1% during the 2nd quarter. Goldman Sachs Group Inc. now owns 935,685 shares of the medical instruments supplier’s stock worth $88,441,000 after purchasing an additional 86,022 shares in the last quarter. Finally, Hermes Investment Management Ltd. lifted its holdings in West Pharmaceutical Services by 3.3% during the 3rd quarter. Hermes Investment Management Ltd. now owns 908,655 shares of the medical instruments supplier’s stock worth $87,467,000 after purchasing an additional 28,955 shares in the last quarter. 90.10% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: “Grandfield & Dodd LLC Purchases Shares of 2,088 West Pharmaceutical Services, Inc. (WST)” was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark law. The original version of this news story can be read at https://www.thecerbatgem.com/2017/11/11/grandfield-dodd-llc-purchases-shares-of-2088-west-pharmaceutical-services-inc-wst.html.

Shares of West Pharmaceutical Services, Inc. (NYSE WST) traded up $0.22 during midday trading on Friday, reaching $101.65. The company’s stock had a trading volume of 252,600 shares, compared to its average volume of 367,288. The company has a market cap of $7,560.00, a price-to-earnings ratio of 43.72, a P/E/G ratio of 2.16 and a beta of 1.14. The company has a debt-to-equity ratio of 0.15, a current ratio of 2.59 and a quick ratio of 1.87. West Pharmaceutical Services, Inc. has a fifty-two week low of $76.87 and a fifty-two week high of $103.36.

West Pharmaceutical Services (NYSE:WST) last announced its earnings results on Thursday, October 26th. The medical instruments supplier reported $0.67 earnings per share for the quarter, topping analysts’ consensus estimates of $0.53 by $0.14. The business had revenue of $398.20 million for the quarter, compared to analyst estimates of $386.02 million. West Pharmaceutical Services had a return on equity of 14.47% and a net margin of 12.12%. The company’s quarterly revenue was up 5.7% compared to the same quarter last year. During the same period in the prior year, the company earned $0.53 EPS. sell-side analysts expect that West Pharmaceutical Services, Inc. will post 2.76 EPS for the current fiscal year.

A number of analysts recently issued reports on the company. Wells Fargo & Company increased their price objective on West Pharmaceutical Services from $105.00 to $112.00 and gave the stock an “outperform” rating in a report on Friday, October 27th. Bank of America Corporation cut West Pharmaceutical Services from a “buy” rating to a “neutral” rating and set a $98.00 price objective on the stock. in a report on Tuesday, October 17th. Stephens assumed coverage on West Pharmaceutical Services in a report on Tuesday, October 3rd. They set an “equal weight” rating and a $99.00 price objective on the stock. Zacks Investment Research raised West Pharmaceutical Services from a “sell” rating to a “hold” rating in a report on Wednesday, September 27th. Finally, Jefferies Group LLC raised West Pharmaceutical Services from a “hold” rating to a “buy” rating and increased their price objective for the stock from $96.00 to $115.00 in a report on Friday, September 15th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have given a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $106.00.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc is a manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. The Company’s products include vial containment solutions, prefillable systems, self-injection platforms, cartridge systems and components, reconstitution and transfer systems, intradermal delivery solutions, specialty components, and contract manufacturing and analytical services.

Want to see what other hedge funds are holding WST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for West Pharmaceutical Services, Inc. (NYSE:WST).

Institutional Ownership by Quarter for West Pharmaceutical Services (NYSE:WST)

Receive News & Stock Ratings for West Pharmaceutical Services Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services Inc. and related stocks with our FREE daily email newsletter.